MDM2 protein
are powerful oncogene which is overexpressed in various cancers, including
breast cancer and sarcoma. There are many small molecule drug candidates that
are being developed as MDM2 protein inhibitors as monotherapy or combination
therapy for the treatment of various cancers.
Combination therapies are more
effective than monotherapy in certain cases. The therapeutic strategies aim at
blocking MDM2 expression, blocking the physical interaction between MDM2 and
p53, modulating the E3 ubiquitin ligase activity of MDM2 and targeting the
MDM2-p53 (protein–protein) complex, for the treatment of various indications.
Request to Get the Sample Pages at:
MDM2 protein therapies have shown positive clinical results
for the treatment of various cancers. Also, researches have demonstrated that
additional biomarkers are required to be identified to increase the chances of
clinical success as mutations in p53 can lead to resistance to MDM2 inhibitors.
Access Detailed Report Summary: https://www.pharmaproff.com/report/mdm2-protein-inhibitors
Daiichi Sankyo Company Limited is in the process of
developing DS-3032 as a proto-oncogene protein C MDM2 inhibitor for the
treatment of leukemia, and solid cancers. Some of the other companies having
pipeline of MDM2 protein inhibitors include Aileron Therapeutics Inc., Amgen
Inc., and F. Hoffmann-La Roche Ltd.
